World Hepatitis Summit 2022- Dates announcement

The World Hepatitis Alliance (WHA) is pleased to announce that the World Hepatitis Summit (WHS) will return in 2022 with a hybrid meeting. This will combine an in-person event for those able to attend along with a virtual option for those unable to travel. The three-day summit will take place in Bangkok, Thailand, from June 8-10, with a one-day pre-conference meeting exclusively for WHA members held on 7 June. 

The WHS is the only global hepatitis conference focused on public health and hepatitis elimination. The summit in 2022, co-sponsored by the World Health Organization (WHO) and organised by WHA, will bring together the international hepatitis community for an unrivalled opportunity to focus on implementing the viral hepatitis response. By bringing together civil society and community organisations, people with lived experience and the affected community, health ministers, clinicians and programme managers, WHS 2022 will drive progress to make the elimination of viral hepatitis by 2030 a reality.   

Su Wang, WHA President and Chair of the WHS Programme Committee, said:

It is time to bring the hepatitis community together once again, to both assess the impact that Covid-19 has had on hepatitis elimination efforts and to explore ways in which we can accelerate action and commitment towards hepatitis elimination.   

We look forward to welcoming as many participants as possible in person in Bangkok while ensuring that there is a virtual option allowing for full participation from people unable to attend in person. On behalf of the programme committee, we look forward to seeing you at WHS 2022.”    

The theme of WHS 2022 is “Achieving the elimination of viral hepatitis within evolving health systems”. 


“With COVID-19 resulting in radical disruption to health systems and the global health agenda increasingly focussing on Universal Health Coverage (UHC), WHS 2022 will explore the challenges and opportunities for hepatitis programmes within these evolving health systems,” said Cary James, WHA, CEO  
 

WHS 2022 will be the third World Hepatitis Summit; preceding summits were WHS 2015 held in Glasgow, Scotland and WHS 2017 held in São Paolo, Brazil. Previous summits were landmark events in the global hepatitis response. WHS 2022 will accelerate progress towards hepatitis elimination in the face of COVID-19. With less than a decade to go to reach the 2030 elimination targets, it has never been more important to bring the hepatitis community together again.  


Registration and calls for abstracts will open in the coming months.
For more information about the summit, please visit www.worldhepatitissummit.org

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close